TargetBeta
LAG3
lymphocyte activating 3 · also CD223 · CD molecules
4 programs in company-led studies act on LAG3, from 4 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| relatlimabrule | Bristol-Myers Squibb | phase 4 | 195 running | – | NCIt |
| fianlimabrule | Regeneron Pharmaceuticals | phase 3 | 109 running | – | NCIt |
| Anti-PD-1/LAG-3 Bispecific Antibody AK129rule | Akeso | phase 2 | 42 running | PDCD1 | NCIt |
| TQB2252 | Sino Biopharmaceutical | phase 1 | 11 running | PDCD1 | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Melanoma, 2 programs
- Neoplasms, 2 programs
- Squamous Cell Carcinoma of Head and Neck, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Ependymoma, 1 program
- Hodgkin Disease, 1 program
- Stomach Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026TQB2252 · Sino Biopharmaceutical · phase 1 · NCT06649656
- Dec 2026Anti-PD-1/LAG-3 Bispecific Antibody AK129 · Akeso · phase 2 · NCT06943820
- Jan 15, 2027fianlimab · Regeneron Pharmaceuticals · phase 3 · NCT05608291
- May 26, 2029relatlimab · Bristol-Myers Squibb · phase 4 · NCT07459543
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.